rs397516000
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM5PP3_ModeratePP5
The NM_000256.3(MYBPC3):c.3065G>C(p.Arg1022Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000521 in 1,611,220 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1022S) has been classified as Pathogenic.
Frequency
Consequence
NM_000256.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.3065G>C | p.Arg1022Pro | missense_variant | 29/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.3065G>C | p.Arg1022Pro | missense_variant | 29/35 | 5 | NM_000256.3 | ENSP00000442795.1 | ||
MYBPC3 | ENST00000399249.6 | c.3065G>C | p.Arg1022Pro | missense_variant | 28/34 | 5 | ENSP00000382193.2 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152224Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000243 AC: 6AN: 246674Hom.: 0 AF XY: 0.0000298 AC XY: 4AN XY: 134018
GnomAD4 exome AF: 0.0000535 AC: 78AN: 1458878Hom.: 0 Cov.: 33 AF XY: 0.0000482 AC XY: 35AN XY: 725852
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152342Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74494
ClinVar
Submissions by phenotype
Hypertrophic cardiomyopathy Pathogenic:2Uncertain:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 03, 2023 | This sequence change replaces arginine, which is basic and polar, with proline, which is neutral and non-polar, at codon 1022 of the MYBPC3 protein (p.Arg1022Pro). This variant is present in population databases (rs397516000, gnomAD 0.005%). This missense change has been observed in individuals with hypertrophic or dilated cardiomyopathy (PMID: 20433692, 22857948, 23396983, 24093860, 28771489, 30847666). ClinVar contains an entry for this variant (Variation ID: 42682). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Arg1022 amino acid residue in MYBPC3. Other variant(s) that disrupt this residue have been observed in individuals with MYBPC3-related conditions (PMID: 22765922, 28790153), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 16, 2019 | The p.Arg1022Pro variant has been reported in >15 heterozygous individuals with HCM (Bos 2014, Brito 2005, Brito 2012, Cecconi 2016, Hazebroek 2015, Lopes 2013, Mademont-Soler 2017, Millat 2010, Walsh 2016, van Velzen 2018, Montserrat 2011- pers. comm., LMM data), 1 compound heterozygous individual with HCM (Rodriguez-Garcia 2010), and 1 compound heterozygous individual with DCM (Hazebroek 2015). This variant segregated with disease in 3 affected individuals and was absent in 2 family members with borderline LVH in one family (Rodriguez-Garcia 2010). This variant has been reported in ClinVar (Variation ID: 42682) and has been seen in 0.005% (6/127826) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis are consistent with pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant HCM. ACMG/AMP Criteria applied: PS4, PM2_Supporting, PP1, PP3. - |
Uncertain significance, no assertion criteria provided | research | Zaffran Lab, Genetics of Cardiac Diseases Laboratory, Marseille Medical Genetics | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Feb 05, 2024 | This missense variant replaces arginine with proline at codon 1022 of the MYBPC3 protein. Computational prediction tools and conservation analyses suggest that this variant may have a deleterious impact on the protein function. To our knowledge, functional assays have not been performed for this variant. This variant has been reported in over ten individuals affected with hypertrophic cardiomyopathy (PMID: 20433692, 20624503, 20800588, 22857948, 23396983, 23782526, 24093860, 27532257, 28771489, 30847666, 31983221, 32841044, 32880476, 33495596, 33495597). This variant was observed together with pathogenic variants in different genes that could explain the observed phenotype (PMID: 20624503, 23782526; communication with an external laboratory). This variant has been reported in six affected individuals from two different families, but two possibly affected individuals did not carry this variant (PMID: 20433692). This variant has been identified in 7/278058 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant has been classified as a Variant of Uncertain Significance. - |
Cardiomyopathy Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Jun 02, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Mar 09, 2023 | This missense variant replaces arginine with proline at codon 1022 of the MYBPC3 protein. Computational prediction tools and conservation analyses suggest that this variant may have a deleterious impact on the protein function. To our knowledge, functional assays have not been performed for this variant. This variant has been reported in over ten individuals affected with hypertrophic cardiomyopathy (PMID: 20433692, 20624503, 20800588, 22857948, 23396983, 23782526, 24093860, 27532257, 28771489, 30847666, 31983221, 32841044, 32880476, 33495596, 33495597). This variant was observed together with pathogenic variants in different genes that could explain the observed phenotype (PMID: 20624503, 23782526; communication with an external laboratory). This variant has been reported in six affected individuals from two different families, but two possibly affected individuals did not carry this variant (PMID: 20433692). This variant has been identified in 7/278058 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant has been classified as a Variant of Uncertain Significance. - |
Hypertrophic cardiomyopathy 4 Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Genetics and Molecular Cardiology, University of São Paulo | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Left ventricular noncompaction 10 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Jul 25, 2019 | - - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 17, 2024 | The p.R1022P variant (also known as c.3065G>C), located in coding exon 29 of the MYBPC3 gene, results from a G to C substitution at nucleotide position 3065. The arginine at codon 1022 is replaced by proline, an amino acid with dissimilar properties. This variant was reported in multiple individuals with features consistent with hypertrophic cardiomyopathy (HCM) (Brito D et al. Rev Port Cardiol, 2005 Sep;24:1137-46; Lopes LR et al. J Med Genet, 2013 Apr;50:228-39; Millat G et al. Eur J Med Genet, 2010 Jul;53:261-7; Rodríguez-García MI et al. BMC Med Genet, 2010 Apr;11:67; Marsiglia JD et al. Am Heart J, 2013 Oct;166:775-82; Cecconi M et al. Int J Mol Med, 2016 Oct;38:1111-24; Mademont-Soler I et al. PLoS One, 2017 Aug;12:e0181465; Walsh R et al. Genet Med, 2017 Feb;19:192-203; Sheikh N et al. Circulation, 2018 09;138:1184-1194; van Lint FHM et al. Neth Heart J, 2019 Jun;27:304-309). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Apr 15, 2021 | Identified in six individuals with HCM from two Spanish families, however, two relatives with suspected diagnoses of HCM did not harbor the R1022P variant (Rodriguez-Garcia et al., 2010); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 20624503, 27600940, 26383716, 22857948, 16335287, 20800588, 23396983, 24093860, 25351510, 27532257, 23782526, 24793961, 26743238, 20433692, 28771489, 29661763, 30847666, 32880476) - |
Primary familial hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Dec 02, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at